Helicobacter Pylori Treatment with Alternative Drugs: Good and Cheap for Developing Countries Furazolidone-Based Treatment- Omeprazole, Furazolidone and Tetracycline Open-Label Trial in A Developing Country: Why Not?

Abstract

a. Past or present duodenal and/or gastric ulcer, with or without complications. b. Following resection of gastric cancer. AbstractObjective: To analyze eradication rate and evaluate collateral effects of an existing alternative dosage, comprised of Omeprazole, tetracycline and furazolidone for 7 days in patients with gastric and/or duodenal ulcers and first-degree relatives of family members with a diagnosis of gastric cancer with positive study for Helicobacter pylori (H. pylori) and treatment-naive. Design and location:The out patients from the Clinic of the Gastroenterology Department of the ABC Medical School, Santo Andre, SP-Brazil. Results: 85 patients were included in the study of which 55 completed the treatment. 95% of the patients had an adequate adherence to the treatment. 49% of the patients analyzed by protocol had at least one side effect, with the most common being nausea (24%) and there was no statistical difference between the relation of side effects and lapse of treatment for H. pylori. 5% (3 patients) interrupted the treatment. The eradication rate per protocol (PP) was 96% (95%CI: 84% to 100%) for patients who completed the treatment. Patients and methods: Conclusion:The therapy based on Omeprazole, tetracycline and furazolidone in the dosages proposed represents a good and low-cost alternative to the first-line therapy to eradicate infection by H. pylori in treatment-naive patients in a developing country.

Evaluation the relationship between the antibodies of Helicobacter pylori and Interleukin-6 in patients with gastritis in Kirkuk province

“…The description of that result were this bacteria is capable to colonize and persist in the mucus layers of the human stomach. Infection affects almost half of the world's population and it is responsible for the most frequent and persistent infection of the gastrointestinal tract universal [23].…”

Helicobacter pyloriInfection in Different Age Groups of Patients with Gastric Diseases.

“…This bacteria is able to colonizeand persist in the mucuslayersof the human stomach. Infection affects almost half of the world's population and it isresponsible for the most frequent and persistent infection of the gastrointestinal tract worldwide (2) .One study mentioned that adults have a continuous risk of H. pylori infection, resulting in increased seroprevalence during lifetime as a function of age (3) .…”